Navigation Links
Hypertension Diagnostics Announces Fiscal Year 2007 Results
Date:9/27/2007

ST. PAUL, Minn., Sept. 27 /PRNewswire-FirstCall/ -- Hypertension Diagnostics, Inc. (OTC Bulletin Board: HDII), today announced audited financial results for the fiscal year ended June 30, 2007.

Revenue for fiscal year 2007 totaled $1,878,840 compared to $1,789,546 in the prior year ended June 30, 2006, which represents a 5% increase. The Company incurred a net loss of $504,011 for fiscal year 2007, or $(.01) per share, compared with a net loss of $1,272,742 for fiscal year 2006, or $(.04) per share. Included in the net loss for fiscal year 2007 are total non-cash charges (expenses associated mainly with stock compensation, depreciation, stock options) of $290,989. The Company reported a cash balance on June 30, 2007 of $1,376,632.

Fourth quarter revenue of $438,481, for fiscal year 2007 compared to $295,536 for fiscal year 2006, represented a 48% increase. Revenue for the fourth quarter of fiscal year 2007 decreased by 6.5% compared with $469,151 for the third quarter of fiscal year 2007.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2006 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

Hypertension Diagnostics, Inc.

Summary Financial Data

Statements of Operations

Three Months Ended Twelve Months Ended

June 30 June 30

2007 2006 2007 2006

Revenue:

Equipment sales $ 379,100 $ 209,500 $ 1,593,706 $ 1,352,486

Equipment rental 56,707 84,769 255,247 418,979

Service/contract

income 2,674 1,267 29,887 18,081

438,481 295,536 1,878,840 1,789,546

Cost of Sales 18,939 1,483 66,413 90,447

Gross Profit 419,542 294,053 1,812,427 1,699,099

Expenses:

Selling, general

and administrative 447,678 685,958 2,381,310 3,018,624

Total Expenses 447,678 685,958 2,381,310 3,018,624

Operating Loss (28,136) (391,905) (568,883) (1,319,525)

Other Income:

Interest income 14,558 16,338 56,773 46,783

Gain on sale of

property and

equipment - - 8,099 -

Total Other

Income 14,558 16,338 64,872 46,783

Net Loss $ (13,578) $ (375,567) $ (504,011) $(1,272,742)

Basic and Diluted

Net Loss

per Share $ (.00) $ (.01) $ (.01) $ (.04)

Weighted Average

Shares

Outstanding 39,620,262 39,714,469 39,793,320 35,219,474

Balance Sheet Data

June 30, 2007 June 30, 2006

Cash and cash

equivalents $ 1,376,632 $ 1,722,913

Total current assets 1,976,825 2,257,390

Total assets 2,020,385 2,345,949

Total current liabilities 582,124 489,081

Accumulated deficit (26,482,330) (25,978,319)

Total shareholders' equity 1,426,143 1,840,414

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.

Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Website: http://www.hdii.com


'/>"/>
SOURCE Hypertension Diagnostics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
2. New viewpoint on Hypertension
3. Hypertension drugs could lower Disability
4. Preventing white coat hypertension
5. New drug for hypertension
6. FDA Approves Remodulin for Pulmonary Hypertension
7. Risk of dementia reduced hypertension drugs
8. Glaucoma & Ocular Hypertension more likely in patients with refractive errors
9. Hypertension lowered by Bedtime Dosing
10. An hour of exercise a week cuts hypertension
11. Better Treatment For Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... Fresenius Vascular ... in minimally invasive techniques to treat and manage a wide range of vascular conditions, ... rebranding initiative. With more than 65 centers represented by more than 40 local brands, ...
(Date:6/20/2017)... ... June 20, 2017 , ... MindTouch , the leading ... proud to announce Touchpoints integrations. MindTouch Touchpoints easily integrate product documentation ... to provide a seamless customer experience. , Truly “plug and play,” Touchpoints are ...
(Date:6/20/2017)... ... June 20, 2017 , ... New, state-of-the-art magnetic ... is providing physicians with advanced capabilities for diagnosing and treating disease. , ... enabling doctors to get a more accurate look inside the patient’s body. The ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... systems industry has been selected as the partner of choice by Amtrak to ... railroad service that provides medium- and long-distance intercity service in the contiguous United ...
(Date:6/20/2017)... Pass, OR (PRWEB) , ... June 20, 2017 ... ... Recently, on her nationally syndicated radio program, The Sharon Kleyne Hour Power of ... EyeMist®, Kleyne launched right in to the world’s water crisis and how it ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... -- NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company focused ... positive biochemical outcomes related to more frequent hemodialysis with ... be presented at the ERA-EDTA Congress being held June ... The research was conducted by the ... Europe (KIHDNEy) Cohort team with ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences ... Company specializing in the development of cannabinoid-based drugs, ... a company overview at three upcoming scientific and ... Annual LD Micro Invitational: ... Date:                     ...
(Date:5/24/2017)...  ivWatch LLC today announced the launch of ... enable seamless integration of ivWatch,s groundbreaking IV infiltration ... and other devices. By integrating ivWatch technology into ... health care customers deliver a higher level of ... therapy. "The ivWatch OEM Board provides ...
Breaking Medicine Technology: